Terms: = Bone cancer AND TCL1A, P56279, 8115, ENSG00000100721, TCL1
51 results:
1. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
Shumilov E; Mazzeo P; Ghandili S; Künstner A; Weidemann S; Banz Y; Ströbel P; Pollak M; Kolloch L; Beltraminelli H; Kerkhoff A; Mikesch JH; Schliemann C; Haase D; Wulf G; Legros M; Lenz G; Feldmeyer L; Pabst T; Witte H; Gebauer N; Bacher U
Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088
[TBL] [Abstract] [Full Text] [Related]
2. Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature.
Gjelberg HK; Helgeland L; Liseth K; Micci F; Sandnes M; Russnes HG; Reikvam H
Curr Oncol; 2023 Nov; 30(11):10007-10018. PubMed ID: 37999147
[TBL] [Abstract] [Full Text] [Related]
3. Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm.
He J; Garcia MB; Connors JS; Nuñez CA; Quesada AE; Gibson A; Roth M; Cuglievan B; Pemmaraju N; McCall D
J Pediatr Hematol Oncol; 2023 Nov; 45(8):e1001-e1004. PubMed ID: 37661300
[TBL] [Abstract] [Full Text] [Related]
4. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A; Sweet K
J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
[TBL] [Abstract] [Full Text] [Related]
5. IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression.
Tang H; Panse G; Braddock D; Perincheri S; Xu ML; McNiff JM
J Cutan Pathol; 2023 Jul; 50(7):595-600. PubMed ID: 37082914
[TBL] [Abstract] [Full Text] [Related]
6. [Blastic plasmacytoid dendritic cell neoplasm: A clinico-pathological retrospective analysis of thirteen cases].
Nong L; Wang W; Liang L; Li D; Li X; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):308-314. PubMed ID: 37042142
[TBL] [Abstract] [Full Text] [Related]
7. T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.
Hu Z; Medeiros LJ; Xu M; Yuan J; Peker D; Shao L; Tang Z; Mai B; Thakral B; Rios A; Hu S; Wang W
Am J Clin Pathol; 2023 Apr; 159(4):325-336. PubMed ID: 36883805
[TBL] [Abstract] [Full Text] [Related]
8. Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review.
Wang Y; Xiao L; Yin L; Zhou L; Deng Y; Deng H
Medicine (Baltimore); 2023 Feb; 102(7):e32904. PubMed ID: 36800625
[TBL] [Abstract] [Full Text] [Related]
9. From the archives of MD Anderson cancer Center: Aleukemic T-prolymphocytic leukemia, a rare presentation and review of the literature.
Nahmod KA; Thakral B; Aakash FNU; Iyer SP; Medeiros LJ; Quesada AE
Ann Diagn Pathol; 2023 Feb; 62():152077. PubMed ID: 36549077
[TBL] [Abstract] [Full Text] [Related]
10. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
[TBL] [Abstract] [Full Text] [Related]
11. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
[TBL] [Abstract] [Full Text] [Related]
12. Spontaneous Regression of Blastic Plasmacytoid Dendritic Cell Neoplasm Following Sepsis by Serratia marcescens: A Case Report and Literature Review.
Suzuki A; Abe S; Koyama K; Suzuki S; Nagao M; Kobayashi M; Nomura J; Tsutsumi T; Takeda T; Oka Y; Shirota Y; Takasawa N; Kodera T; Okitsu Y; Takahashi S; Ichinohasama R; Kameoka J
Intern Med; 2021; 60(6):927-933. PubMed ID: 33716255
[TBL] [Abstract] [Full Text] [Related]
13. Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia.
Rovida A; Maccalli C; Scarfò L; Dellabona P; Stamatopoulos K; Ghia P
Clin Cancer Res; 2021 Feb; 27(3):729-739. PubMed ID: 33051305
[TBL] [Abstract] [Full Text] [Related]
14. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
Zhang X; Sun J; Yang M; Wang L; Jin J
Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
[TBL] [Abstract] [Full Text] [Related]
15. Genetic Underpinnings of Musculoskeletal Pain During Treatment With Aromatase Inhibitors for Breast cancer: A Biological Pathway Analysis.
Zhu Y; Koleck TA; Bender CM; Conley YP
Biol Res Nurs; 2020 Apr; 22(2):263-276. PubMed ID: 31847542
[TBL] [Abstract] [Full Text] [Related]
16. TBET-expressing Th1 CD4
Roessner PM; Hanna BS; Öztürk S; Schulz R; Llaó Cid L; Yazdanparast H; Scheffold A; Colomer D; Stilgenbauer S; Lichter P; Seiffert M
Br J Haematol; 2020 Apr; 189(1):133-145. PubMed ID: 31724172
[TBL] [Abstract] [Full Text] [Related]
17. Par-4 overexpression impedes leukemogenesis in the Eµ-tcl1 leukemia model through downregulation of NF-κB signaling.
Greene JT; Mani R; Ramaswamy R; Frissora F; Yano M; Zapolnik K; Harrington B; Wasmuth R; Tran M; Mo X; McKenna M; Rangnekar VM; Byrd JC; Bondada S; Muthusamy N
Blood Adv; 2019 Apr; 3(8):1255-1266. PubMed ID: 30987970
[TBL] [Abstract] [Full Text] [Related]
18. The role of the genetic abnormalities, epigenetic and microRNA in the prognosis of chronic lymphocytic leukemia.
Tari K; Shamsi Z; Reza Ghafari H; Atashi A; Shahjahani M; Abroun S
Exp Oncol; 2018 Dec; 40(4):261-267. PubMed ID: 30593759
[TBL] [Abstract] [Full Text] [Related]
19. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
[TBL] [Abstract] [Full Text] [Related]
20. Actionable perturbations of damage responses by tcl1/ATM and epigenetic lesions form the basis of T-PLL.
Schrader A; Crispatzu G; Oberbeck S; Mayer P; Pützer S; von Jan J; Vasyutina E; Warner K; Weit N; Pflug N; Braun T; Andersson EI; Yadav B; Riabinska A; Maurer B; Ventura Ferreira MS; Beier F; Altmüller J; Lanasa M; Herling CD; Haferlach T; Stilgenbauer S; Hopfinger G; Peifer M; Brümmendorf TH; Nürnberg P; Elenitoba-Johnson KSJ; Zha S; Hallek M; Moriggl R; Reinhardt HC; Stern MH; Mustjoki S; Newrzela S; Frommolt P; Herling M
Nat Commun; 2018 Feb; 9(1):697. PubMed ID: 29449575
[TBL] [Abstract] [Full Text] [Related]
[Next]